DAZAP1

DAZ-associated protein 1 · Q96EP5 · DAZAP1 on Sugi Atlas →

0 patent compounds predicted against DAZAP1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to DAZAP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. PHASE3UNKNOWN
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) PHASE2/PHASE3COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer PHASE2UNKNOWN
Decitabine in Treating Patients With Myelofibrosis PHASE2ACTIVE_NOT_RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies PHASE1/PHASE2WITHDRAWN
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia PHASE2ACTIVE_NOT_RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia PHASE1COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN
Analysis of DNA Methylation in Spondyloarthritis nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Diagnosis of Inflammatory Bowel Disease nanNOT_YET_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DAZAP1 binder may also engage these)

ProteinNameSimilarity
Q9JII5 1.000 Q9JII5 →
Q98SJ2 1.000 Q98SJ2 →
Q920Q6 0.988 Q920Q6 →
Q3SWU3 0.987 Q3SWU3 →
MSI2 RNA-binding protein Musashi homolog 2 0.987 landscape →
P48809 0.986 P48809 →
Q5ZI72 0.985 Q5ZI72 →
Q63627 0.984 Q63627 →
HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B 0.984 landscape →
Q8W034 0.984 Q8W034 →
Q22037 0.983 Q22037 →
A2Q848 0.983 A2Q848 →
Q02926 0.983 Q02926 →
A7VJC2 0.983 A7VJC2 →
HNRNPD Heterogeneous nuclear ribonucleoprotein D0 0.983 landscape →
Q32P51 0.983 Q32P51 →
O95104 0.982 O95104 →
Q7TMK9 0.982 Q7TMK9 →
Q9SQV1 0.982 Q9SQV1 →
SYNCRIP Heterogeneous nuclear ribonucleoprotein Q 0.982 landscape →
Q5RBU8 0.982 Q5RBU8 →
O43347 0.982 O43347 →
Q640A2 0.982 Q640A2 →
Q9C652 0.981 Q9C652 →
A4QUF0 0.981 A4QUF0 →
Q7TP47 0.981 Q7TP47 →
O94432 0.981 O94432 →
Q9JJ54 0.981 Q9JJ54 →
Q5R8F7 0.981 Q5R8F7 →
P51992 0.980 P51992 →